Adeno-associated virus (AAV) serotype-9 (AAV-9) has attracted great attention as an optimal vehicle for body-wide gene delivery. Here we examined the effect of animal age (newborn vs adult) and the route of administration (intravenous vs intra-arterial) on systemic AAV-9 transduction. We delivered an alkaline phosphatase (AP) reporter gene AAV vector (AV.RSV.AP) to either newborn (via either the facial vein or the left ventricular cavity) or adult (via tail vein) C57Bl/ 10 mice. At 12 weeks' postinfection, we examined the AP expression. We observed efficient transduction in multiple skeletal muscles and the heart, irrespective of the age or delivery route. However, the soleus muscle, which consists mainly of slow-twitch myofibers, was poorly transduced. Besides striated muscle, we also found consistent high-level transduction in the lung. Abundant AP-positive cells were seen in alveolar cells and vasculature, but not in bronchioles. Interestingly, several organs demonstrated an age-dependent profile. In particular, the aorta, liver and kidney were preferentially transduced in adult mice while the inner layer of retina was strongly transduced only following the neonatal administration. Taken together, our results demonstrate the robustness of intravascular AAV-9 delivery for muscle and lung gene therapy applications. The unique expression patterns in the aorta, liver, kidney and retina call for special attention when designing AAV-9 gene therapy applications for these organs.
Systemic-gene delivery holds great promise for many gene therapy applications. The recent discovery of several novel adeno-associated virus (AAV) serotypes opens the door for global transduction from a single intravascular injection. Among the newly described AAV serotypes, AAV serotype-9 (AAV-9) stands out as a particularly attractive vehicle because of its superior performance in skeletal muscle, the heart and the lung. [1] [2] [3] To reach every tissue/organ in the body, a gene-therapy vector can be introduced into the bloodstream through either venous or arterial circulation. All published studies on intravascular AAV-9 delivery have utilized the venous pathway. [1] [2] [3] It is not clear whether one can achieve similar efficiency through the intra-arterial route. Theoretically one may speculate advantages/limitations for each delivery scheme based on anatomy. For example, following intravenous (i.v.) injection, the returning blood will bring AAV to the right ventricle and the lung first. In contrast, following intra-arterial injection, AAV will reach muscle and all other tissues first and the lung last. The spatial and temporal differences between these routes may alter transduction characteristics in different tissues and/or organs.
Another relevant issue in clinical gene therapy is patient age. Many diseases affect both newborn and adult patients. While some diseases are diagnosed late in life, a number of inherited diseases can be identified through neonatal screening. Adeno-associated virus gene therapies that are developed for adult patients (such as the timing, the route and the dose of vector delivery) may not suit well for neonatal patients and vice versa. Exploring the age-associated differences in AAV-9 transduction may have significant clinical implications.
To further develop AAV-9 for systemic-gene therapy, we compared the level of transgene expression through different routes of administration (i.v. vs intra-arterial, all in neonatal mice) and at different ages (neonatal vs adult, all through venous delivery). For i.v. administration, we delivered AAV-9 via facial vein of newborn mice or tail vein of adult mice. For intra-arterial administration, we injected AAV-9 directly into the left ventricular cavity of neonatal mice. 4 For age comparison, we injected 3.5 Â 10 11 vg particles to each newborn mouse (1.2 Â 10 11 vg g À1 body weight, 50 ml g À1 body weight) and 1 Â 10 12 vg particles to each adult mouse (7 Â 10 10 vg g À1 body weight, 20 ml g À1 body weight). We first examined expression in skeletal muscle. For reasons yet unknown, skeletal muscle seems to be particularly amenable to systemic AAV infection. Highlevel transduction has been reported for AAV-1, 6, 8 and 9 by various groups. [1] [2] [3] [5] [6] [7] Consistent with these reports, we observed robust alkaline-phosphatase (AP) expression in the majority of skeletal muscles we examined ( Figure 1, Supplementary Figure 1) . Skeletal muscle is composed of fast-and slow-twitch myofibers. It has been shown that AAV-2 preferentially transduces slow-twitch fibers while AAV-6 transduces both fiber types efficiently. [8] [9] [10] It is not clear whether AAV-9 displays a fiber type preference. To address this issue, we compared AP expression in the tibialis-anterior (TA) muscle (fast twitch predominant) and the soleus muscle (slow twitch predominant). On histochemical staining, the TA muscle showed much more intense staining than that of the soleus muscle ( Figure 1a ). Quantification of AP activity in muscle lysate revealed a five-fold difference between the TA muscle and the soleus muscle ( Figure 1b , Supplementary Methods). Despite a low transduction in the soleus muscle in general, we did observe a few intensely stained myofibers in this muscle ( Figure 1a) . To determine the nature of these highly transduced-myofibers, we performed immunostaining with anti-slow and anti-fast myosin antibodies (Supplementary Figure 2) . We found that the majority of the AP-positive myofibers were fast-twitch myofibers.
Next, we examined cardiac muscle. Superior heart transduction is recognized as a unique feature of AAV-9 following i.v. injection. [1] [2] [3] However, at low dose, AAV-9 cannot transduce all cardiomyocytes. Inagaki et al. achieved whole heart transduction by increasing AAV dose. We have previously shown relatively efficient Figure 1 Adeno-associated virus (AAV)-9 preferentially transduces fast-twitch muscle. AV.RSV.AP, an AAV-9 vector expressing the heatresistant human placental alkaline phosphatase gene, was generated according to our published protocol. In newborn BL10 mice (40 h old), 1.2 Â 10 11 vg g À1 body weight (3.5 Â 10 11 vg/mouse) of AAV were delivered via either the facial vein (newborn venous) or the left ventricle (newborn arterial). In young adult BL10 mice (7 week old), 7 Â 10 10 vg g À1 body weight (1 Â 10 12 vg/mouse) of AAV were delivered via tailvein injection (adult venous). Alkaline-phosphatase (AP) expression was examined 12 weeks later by histochemical staining of tissue sections and AP activity assay of tissue lysates, according to our published protocols. (a) Representative AP staining of longitudinal muscle sections from the tibialis anterior(TA) muscle (a predominantly fast-twitch muscle) and the soleus muscle (a predominantly slow-twitch muscle). N ¼ 3 or 4 for each group. Eosin staining outlines myofibers (pink) and AP-positive myofibers show dark-blue staining. Scale bar, 100 mm. (b) Quantitative comparison of AP activity in the TA muscle and the soleus muscle. Mean7s.e.m. N ¼ 12 for each group. The AP activity in uninfected muscles was less than 5 mM mg
À1
. Comparison of the same muscle, the TA or the soleus, showed no statistical difference among different groups (newborn venous, newborn arterial and adult venous; ANOVA, P ¼ 0.592 for the TA muscles, and P ¼ 0.466 for the soleus muscles). *Statistically different between the TA and the soleus muscles (independent sample t-test, P ¼ 0.002). Systemic AAV-9 transduction B Bostick et al Figure 3 Aortic transduction is improved in adult mice following systemic AAV-9 infection but stomach smooth muscle transduction is not influenced by age. Representative photomicrographs depict AP expression in aorta and stomach smooth muscle from the same cohort study described in Figure 1 . N ¼ 3 or 4 for each group. Boxed areas in low-power aorta photomicrographs are enlarged in the corresponding highpower photomicrographs. Arrow: AAV-9 transduced-endothelial layer; arrowhead: AAV-9 transduced-smooth muscle in the aorta of adult mice. Scale bar, 100 mm for low-power photomicrographs of aorta; 10 mm for high-power photomicrographs of aorta; 50 mm for stomach smooth muscle. Systemic AAV-9 transduction B Bostick et al transduction after intracavity injection in the heart. Here, we tested whether delivering AAV-9 directly inside the heart chamber could improve cardiac transduction. 4 As shown in Figure 2 , we observed similar levels of heart transduction in all experimental mice. We did not see any advantage from intracardiac injection. At the dosage used in this study, the majority (although not all) of cardiomyocytes were efficiently transduced irrespective of the age or the administration route.
We also examined transduction profiles in aorta and in smooth muscle of the stomach. The arterial wall has been notoriously difficult to transduce with AAV (reviewed in Baker et al.
11
). We recently showed limited vascularendothelial cell transduction after i.v. AAV-9 infection in newborn mice. However, smooth muscle (either in the aorta or in the esophagus) was poorly transduced. 3 Altering the administration route (from i.v. to intraarterial) did not improve AAV-9 transduction in the aorta and stomach smooth muscle of newborn mice (Figure 3) . Interestingly, we observed much better transduction of the aorta when AAV-9 was delivered to adult mice. However, we did not see an appreciable transduction improvement in stomach smooth muscle in adult mice (Figure 3) .
Utilizing the intra-arterial route, the lung will be the last organ exposed to AAV. Surprisingly, lung transduction was not reduced following intra-arterial delivery (Figure 4 ). We observed high-level alveolar cell transduction in all AAV infected mice. Interestingly, there was limited transduction in the conducting airways although lung-parenchymal vessels were efficiently transduced (Figure 4a) . In contrast to the lung, systemic-AAV-9 transduction of the liver and the kidney was affected by the age. Efficient transduction was achieved only in adult mice. 3 Theoretically, intra-arterial delivery will allow the firsthand access of AAV particles to the liver and the kidney (rather than after AAV has been absorbed by the lung). However, in newborn mice both routes resulted in poor transduction ( Figure 5 ). In most tissues/organs, we observed equal (skeletal muscle, the heart and the lung) or better (the aorta, the liver and the kidney) transduction in adult mice. In sharp contrast, the inner layer of the retina showed a different pattern. Robust AP staining was found only in mice infected at the neonatal stage ( Figure 5 ). Very few cells in the inner retinal layer were transduced when AAV-9 was delivered to adult mice ( Figure 5 ). This suggests that certain tissues may have developmental windows that facilitate AAV-9 transduction.
Intravascular AAV-9 delivery has been proposed for systemic gene therapy. In this study, we evaluated advantages/limitations of different administration routes and the effect of age on systemic AAV-9 transduction. Adeno-associated virus-2 transduction is influenced by the administration route. [12] [13] [14] To determine whether systemic AAV-9 transduction is modulated by the delivery route, we compared i.v. and intra-arterial administration. Considering the distinctive circulation pathways between these delivery routes, one may speculate a preferential transduction in certain tissues/ organs by a particular pathway. Interestingly, we did not see any route-related difference in all the tissues/organs we examined. Although we cannot exclude a dose-saturation effect, our results have provided strong evidence that the route of administration is not a major concern for AAV-9-mediated systemic gene therapy. Under the conditions used in this study, both intra-arterial and i.v. delivery yielded similar transduction efficiency.
The influence of the age on systemic AAV-9 transduction remains to be fully appreciated. Animal age seems to play a minimal role in striated muscles and the lung. These tissues/organs were efficiently transduced in both newborn and adult mice. This allows maximal clinical flexibility for muscle or lung-specific gene therapies such as those directed toward Duchenne-muscular dystrophy. Age-associated differences in the aorta, liver, kidney and retina are quite interesting. They highlight the importance of designing age-specific gene therapy applications for these organs. They also raise some intriguing perspectives on the underlying mechanism(s) and/or the rate-limiting barriers in AAV-9-mediated systemic gene transfer. Future studies aimed at unraveling these differences may lead to novel strategies to further optimize systemic AAV-9 gene therapy.
